(Press-News.org) Contact information: Vicki Cohn
vcohn@liebertpub.com
914-740-2156
Mary Ann Liebert, Inc./Genetic Engineering News
Can personalized tumor vaccines improve interleukin-2 treated metastatic melanoma?
New Rochelle, NY, January 22, 2014—Metastatic melanoma has a poor prognosis, but treatment with high-dose interleukin-2 (IL2) can extend survival. Now, a combination of IL2 therapy and activation of patients' immune systems using personalized vaccines made from their own tumor cells has been shown to improve survival rates even more than IL2 alone, according to a new article in Cancer Biotherapy and Radiopharmaceuticals, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Cancer Biotherapy and Radiopharmaceuticals website.
"High-Dose IL2 in Metastatic Melanoma: Better Survival in Patients Immunized with Antigens from Autologous Tumor Cell Lines" describes a statistically significant improvement in survival for patients who received IL2 plus tumor cell-based immunotherapy. Authors Robert Dillman, Carol DePriest and Stephanie McClure, Hoag Institute for Research and Education, Hoag Family Cancer Institute, and Cancer Biotherapy Research Group, Newport Beach, CA, found that administration of immunotherapy after IL2 treatment resulted in longer patient survival than if individuals were vaccinated before receiving IL2.
"This is an important addition to the literature on IL2 treatment for metastatic melanoma demonstrating that personalized vaccine therapy contributed to an increased survival rate," says Co-Editor-in-Chief Donald J. Buchsbaum, PhD, Division of Radiation Biology, Department of Radiation Oncology, University of Alabama at Birmingham.
INFORMATION:
About the Journal
Cancer Biotherapy and Radiopharmaceuticals, published 10 times a year in print and online, is under the editorial leadership of Editors Donald J. Buchsbaum, PhD and Robert K. Oldham, MD, Lower Keys Cancer Center, Key West, FL. Cancer Biotherapy and Radiopharmaceuticals is the only journal with a specific focus on cancer biotherapy, including monoclonal antibodies, cytokine therapy, cancer gene therapy, cell-based therapies, and other forms of immunotherapy. The Journal includes extensive reporting on advancements in radioimmunotherapy and the use of radiopharmaceuticals and radiolabeled peptides for the development of new cancer treatments. Topics include antibody drug conjugates, fusion toxins and immunotoxins, nanoparticle therapy, vascular therapy, and inhibitors of proliferation signaling pathways. Tables of content and a sample issue are available on the Cancer Biotherapy and Radiopharmaceuticals website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Journal of Interferon & Cytokine Research; Human Gene Therapy, Human Gene Therapy Methods and Human Gene Therapy Clinical Development; and Stem Cells and Development. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is on the Mary Ann Liebert, Inc., publishers website.
Mary Ann Liebert, Inc. 140 Huguenot St., New Rochelle, NY 10801-5215 http://www.liebertpub.com
Phone: (914) 740-2100 (800) M-LIEBERT Fax: (914) 740-2101
Can personalized tumor vaccines improve interleukin-2 treated metastatic melanoma?
2014-01-23
ELSE PRESS RELEASES FROM THIS DATE:
Galaxies on FIRE: Star feedback results in less massive galaxies
2014-01-23
For decades, astrophysicists have encountered a puzzling contradiction: although many galactic-wind models—simulations of how matter is distributed in our universe—predict that the majority of ...
Cooling microprocessors with carbon nanotubes
2014-01-23
"Cool it!" That's a prime directive for microprocessor chips and a promising new solution to meeting this imperative is in the ...
UofL epidemiologist uncovers new genes linked to abdominal fat
2014-01-23
LOUISVILLE, Ky. – Excess abdominal fat can be a precursor to diseases such as cardiovascular disease, type 2 diabetes and cancer. A person's measure of belly fat is reflected in the ratio ...
Humans can use smell to detect levels of dietary fat
2014-01-23
PHILADELPHIA (January 22, 2014) – New research from the Monell Center reveals humans can use the sense of smell to detect dietary fat in food. As food smell almost always is detected before taste, the findings ...
'Watch' cites concern about femoral neck fractures in long-necked modular implants
2014-01-23
Needham, MA.–JBJS Case Connector, an online case report journal published by The Journal of Bone and Joint Surgery, has issued ...
Vulvar condition causing painful sex strikes twice as many Hispanic women
2014-01-23
ANN ARBOR, Mich. — ...
Drug discovery potential of natural microbial genomes
2014-01-23
Scientists at the University of California, San Diego have developed a new genetic platform that allows efficient production of naturally ...
Malaria drug combo could help prevent pregnancy complications in lupus patients
2014-01-23
An anti-malaria drug combination might be useful in helping to prevent pregnancy complications in women with lupus and the related disorder antiphospholipid syndrome, Yale School of Medicine ...
Scripps Florida scientists offer new insight into neuron changes brought about by aging
2014-01-23
JUPITER, FL, January 22, 2013 – How aging affects communication between neurons is not well understood, a gap that makes it more difficult to treat a range of disorders, ...
Image or reality? Leaf research needs photos and lab analysis
2014-01-23
PROVIDENCE, R.I. [Brown University] — Every picture tells a story, but the story digital photos tell about how forests respond to climate change could be incomplete, according to new research.
Scientists ...